Your browser doesn't support javascript.
loading
Safety and Efficacy of Autologous Melanocyte/Keratinocyte Transplantation in Patients with Refractory Stable Vitiligo.
Shahbazi, Atefeh; Abedi Valugerdi, Manuchehr; Kazemi, Sepide; Samadi Kochaksaraei, Sarvenaz; Naseh, Mohammad Hassan; Aghdami, Nasser; Sadeghi, Behnam.
Affiliation
  • Shahbazi A; Department of Cellular and Molecular Biology, School of Biology, College of Science, University of Tehran, Tehran, Iran.
  • Abedi Valugerdi M; Department of Laboratory Medicine, Biomolecular Medicine, Translational Research Center Karolinska, Karolinska Institutet, Stockholm, Sweden.
  • Kazemi S; Department of Clinical Science, Translational Cell therapy Research (TCR), Intervention and Technology, CLINTEC, Karolinska Institutet, Huddinge, Sweden.
  • Samadi Kochaksaraei S; Department of Clinical Science, Translational Cell therapy Research (TCR), Intervention and Technology, CLINTEC, Karolinska Institutet, Huddinge, Sweden.
  • Naseh MH; Hair and skin clinic, Red Crescent Poly Clinic, Red Crescent Society of the Islamic Republic of Iran, Tehran, Iran.
  • Aghdami N; Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
  • Sadeghi B; Department of Infectious Diseases and Tropical Medicines, Tehran University of Medical Sciences, Tehran, Iran.
Dermatology ; 239(6): 919-925, 2023.
Article in En | MEDLINE | ID: mdl-37573775
ABSTRACT

BACKGROUND:

Vitiligo is a common depigmentation skin disease associated with significant psychosocial morbidity and profound effect on the quality of life. The treatment of vitiligo is still a major challenge in the field of dermatology. Currently, topical steroids, calcineurin inhibitors, ultraviolet phototherapy, surgery, and cultured and non-cultured epidermal melanocyte transplantation are used for the treatment of vitiligo. However, the effectiveness of these treatment modalities is limited by the lack of response, long-term treatment periods, high cost, and inevitable adverse effects.

OBJECTIVES:

In this study, we aimed to evaluate the efficacy of intraepidermal injection of autologous non-cultured melanocytes and keratinocytes as an alternative therapy for the refractory and stable (RS) vitiligo.

METHODS:

The treatment procedure was performed on thirty-nine RS vitiligo patients. The autologous skin grafts obtained from the buttock area and epidermis were separated from dermis using dispase. Single-cell autologous melanocytes and keratinocytes were prepared from the epidermis by trypsin/ethylene diamine tetra acetic acid and injected at the concentration of 100-400 × 103 cells/cm2, intra-epidermally to the selected vitiligo lesions. Vitiligo re-pigmentation was monitored employing photography. Photographs were taken prior to and 2, 4, and 6 months after the cell transplantation. Improvement of the skin depigmentation was classified as follows <25% as minimal response, 26-50% as moderate response, 51-75% as good response, and finally 76-100% as excellent response.

RESULTS:

Cell infusion appeared to be safe as none of the patients exhibited any adverse effects. At the end of the sixth month follow-up period, of the treated patients, 12.8% demonstrated an excellent response, 36% exhibited a good response, and 51.2% showed a moderate to minimal response to the administered therapy. Obtained significant p value for Wilcoxon test over the checkpoints at 2nd, 4th, and 6th month (p = 0.03, 0.04, and 0.039, respectively) post-cell transplantation confirmed notable growing trend in the re-pigmentation.

CONCLUSION:

Our findings provide a strong support for the therapeutic efficacy of autologous non-cultured melanocytes and keratinocytes in patients with RS vitiligo.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Vitiligo Language: En Journal: Dermatology Year: 2023 Type: Article Affiliation country: Iran

Full text: 1 Database: MEDLINE Main subject: Vitiligo Language: En Journal: Dermatology Year: 2023 Type: Article Affiliation country: Iran